Black Diamond Therapeutics, Inc.
BDTX$114M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE24 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BDTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
silevertinib (BDTX-1535) monotherapy
Non-Small Cell Lung Cancer
silevertinib in combination with temozolomide
Glioblastoma (GBM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
silevertinib in combination with temozolomide | Phase 2 | Glioblastoma (GBM) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply